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strong determinant of efficacy and specificity in genome edit-
ing. Even though high efficiency of Cas9 delivery is necessary
for optimal editing, its long-term and high levels of expression
correlate with increased off-target activity. We developed vesi-
cles (VEsiCas) carrying CRISPR-SpCas9 ribonucleoprotein
complexes (RNPs) that are efficiently delivered into target cells
through the fusogenic glycoprotein of the vesicular stomatitis
virus (VSV-G). A crucial step for VEsiCas production is the
synthesis of the single guide RNA (sgRNA) mediated by the
T7 RNA polymerase in the cytoplasm of producing cells as
opposed to canonical U6-driven Pol III nuclear transcription.
In VEsiCas, the absence of DNA encoding SpCas9 and sgRNA
allows rapid clearance of the nuclease components in target
cells, which correlates with reduced genome-wide off-target
cleavages. Compared with SpCas9 RNPs electroporation, which
is currently the method of choice to obtain transient SpCas9
activity, VEsiCas deliver the nuclease with higher efficiency
and lower toxicity. We show that a wide variety of cells can
be edited through VEsiCas, including a variety of transformed
cells, induced pluripotent stem cells (iPSCs), and cardiomyo-
cytes, in vivo. VEsiCas is a traceless CRISPR-Cas9 delivery
tool for efficient and safe genome editing that represents
a further advancement toward the therapeutic use of the
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CRISPR-Cas9-mediated genome editing technologies have tremen-
dous potential for both basic and clinical applications.1–10 In
CRISPR-Cas9 applications, cleavage specificity and delivery efficiency
strongly determine the outcome of genome editing.11 High expression
levels of Cas9 for long periods result in high numbers of non-specific
cleavages.12,13 So, by affecting the levels and kinetics of expression, the
method of delivery is a key determinant of editing efficiency and spec-
ificity. In fact, successful genome editing can be obtained through
DNA-free delivery of CRISPR-SpCas9 ribonucleoprotein complexes
(RNPs), which allows transient expression of the RNA-guided
nuclease.14–16 However, the advantages offered by RNP delivery via
physical (electroporation)14 or chemical (lipid- and polymer-basedMolecular Therap
This is an open access article under the CC BY-NC-reagents)16,17 methods are counterbalanced by strong limitations of
their in vivo use.18 Opposed to these methods, viral vectors, including
those of retroviral origin, are widely used for efficient delivery of Cas9
and sgRNA genes both in vitro and in vivo.8,19,20 Nevertheless, these
delivery tools are generally not ideal for transient therapeutic ap-
proaches because of long-term transgene expression and potential
risks for insertional mutagenesis.13,21 Among the non-integrating
vectors, which, in principle, should prevent mutagenic integra-
tion,22–24 those derived from adeno-associated viruses (AAVs) are
suitable only for the expression of small transgenes (no greater than
4 kb) and are thus not fully compatible with the CRISPR-Cas9 tech-
nology. To circumvent the genotoxicity generated by retroviral vec-
tors while preserving viral delivery efficiency, an integration-defective
lentiviral vector (IDLV) vector carrying a single guide RNA (sgRNA)
transgene and packaged with the SpCas9 protein has been devel-
oped.25 A major improvement in the completely traceless delivery
of exogenous protein cargos into cells is potentially offered by the
development of virus-like particles (VLPs).26 The viral origin of
VLPs assures the efficient transduction of target cells even though
no viral genomes is carried by the particles, thus allowing rapid clear-
ance of the shuttled protein and RNAs. VLPs have been mainly used
in the past decade for vaccination purposes27 or for the delivery of
exogenous proteins.26,28 To minimize the viral elements, protein
cargo delivery can be obtained with vesicles made exclusively with
the envelope glycoprotein of the vesicular stomatitis virus (VSV-G).29
Here we developed efficient and traceless delivery of SpCas9 and
sgRNAs consisting of vesicles, named VEsiCas, that carry SpCas9
RNPs and are decorated with the fusogenic VSV-G. To obtain
complete incorporation of sgRNAs into VEsiCas, we exploited they: Nucleic Acids Vol. 12 September 2018 ª 2018 The Authors. 453
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Figure 1. Design and Genome Editing Activity of VEsiCas
(A) EGFP disruption assay with VSV-G/SpCas9 vesicles produced in HEK293T cells. Shown are percentages of EGFP knockout HEK293-EGFP cells generated by
transfection of SpCas9 (SpCas9 plasmid) together with EGFP targeting (sgEGFP5) or control (sgCtr) sgRNA or transduction with VSV-G/SpCas9 vesicles carrying
U6-transcribed sgRNA. Where indicated, HEK293-EGFP cells were pre-transfected with sgEGFP5 or sgCtr (+ pre-sgRNA) prior to VSV-G/SpCas9 vesicle treatment. Data
are presented as mean ± SEM for n = 2 independent experiments. (B) Schematic of VEsiCas production in BSR-T7/5 cells. T7 RNA polymerase, expressed in the cytosol,
regulates cytosolic sgRNA expression by means of the T7 promoter. Vesicles decorated with VSV-G, expressed by BSR-T7/5 producer cells, bud incorporating SpCas9
complexed with sgRNA to form VEsiCas. In target cells, VEsiCas release active SpCas9-sgRNA complexes that enter the nuclei through two nuclear localization sequences
introduced in SpCas9. (C) Genome activity of VEsiCas produced in BSR-T7/5 on HEK293-EGFP cells. Shown are percentages of non-fluorescent HEK293-EGFP cells
following transfection of SpCas9 (SpCas9 plasmid) together with sgRNAs (sgEGFP5 or sgCtr) or treatment with VEsiCas carrying sgRNAs (sgEGFP5 or sgCtr) either with or
without pre-transfection with sgRNAs, as indicated. Data are presented as mean ± SEM for n = 2 independent experiments. (D and E) VEsiCas-mediated editing of the
CXCR4 (D) and VEGFA site3 (E) genomic loci. Percentages of indel formation in HEK293T cells were measured through TIDE analysis following transfection of SpCas9
(SpCas9 plasmid) together with sgRNAs (sgCXCR4, sgVEGFA site3, or sgCtr) or after three sequential treatments with VEsiCas carrying sgRNAs (sgCXCR4, sgVEGFA site3,
or sgCtr). Data are presented as mean ± SEM for n = 2 independent experiments.
Molecular Therapy: Nucleic AcidsT7 RNA polymerase transcription system, which provides high rates
of cytoplasmic sgRNA transcription in producing cells. VEsiCas were
efficiently used in this study for genome editing applications with a
variety of cell types in culture as well as in vivo after injection into
the cardiac muscle of a mouse model. Finally, we tested genome edit-
ing procedures where simultaneous targeting of more than one locus
is required, such as for genomic deletions or for Cas9-nickase appli-
cations, demonstrating the plasticity of VEsiCas for more complex
strategies of genetic surgery.
RESULTS
Design and Development of VEsiCas
VSV-G-induced vesicles have been reported to mediate protein
transfer in the absence of additional viral components.29 We tested
whether VSV-G vesicles could be adapted to DNA-free delivery of
CRISPR-Cas9 RNPs. SpCas9 and an sgRNA toward the EGFP coding
sequence (sgEGFP5) were expressed together with VSV-G in
HEK293T cells, and the derived conditioned clarified medium was454 Molecular Therapy: Nucleic Acids Vol. 12 September 2018applied to a fluorescent reporter cell line, HEK293-EGFP. To evaluate
the efficacy of EGFP editing mediated by the VSV-G vesicle treat-
ments, a comparative analysis was performed with SpCas9-sgRNA
plasmid transfections, used as a benchmark, similar to previous re-
ports.14–16,30 The expression of EGFP was poorly altered under these
conditions, indicating inefficient genome editing, whereas efficient
editing was observed by transfecting SpCas9 together with the sgRNA
(Figure 1A). The limited editing activity was not explained by the lack
of delivered protein because both vesicles and target cells were posi-
tive for SpCas9 (Figure S1A). These results prompted us to evaluate
whether the limiting factor for vesicle activity could be insufficient
incorporation of sgRNA. To this aim, the HEK293-EGFP target cells
were transfected with plasmids expressing sgEGFP5 before treatment
with VSV-G vesicles purified from HEK293T cells expressing
SpCas9-sgRNA. Under these experimental conditions, we obtained
editing levels that were closer to those observed in cells transfected
with SpCas9 and the sgRNA (Figure 1A, compare the sixth and sec-
ond columns of the graph). These results clearly suggested that the
Figure 2. Genome Editing by Multiplexed VEsiCas
(A) Gene deletion using VEsiCas. Shown is gel electro-
phoresis analysis of the EGFP locus deletion obtained
in HEK293-EGFP cells through Multi-VEsiCas (right)
treatment or by transfection with SpCas9 together with
specific sgRNAs (sgEGFP5 and sgEGFPBi) (left). The
amount of deletion (percent) was quantified by densi-
tometry. Arrowheads indicate the expected band corre-
sponding to PCR amplification of the deleted EGFP locus.
(B) Activity of VEsiCas delivering SpCas9 nickase. Shown
are percentages of EGFP knockout cells following incu-
bation with VEsiCas-n, carrying SpCas9 nickase loaded
with sgRNA toward two sites in the EGFP locus
(sgEGFP3gW and sgEGFPBi) or with sgCtr. NT, not
treated. Data are presented as mean ± SEM for n = 2
independent experiments.
www.moleculartherapy.orglimited editing observed with the SpCas9/VSV-G preparations was
due to inefficient delivery of the sgRNA. We speculated that poor
sgRNA delivery could be due to inefficient formation of SpCas9-
sgRNA RNPs during vesicle production. In particular, the RNA poly-
merase III (Pol III)-synthesized sgRNAs in the nuclei may be poorly
coupled with cytoplasmic SpCas9 to form RNPs at cell periphery,
close to the nascent VSV-G vesicles. To test this hypothesis, we em-
ployed a T7 RNA polymerase-driven transcription system31,32 that
catalyzes RNA synthesis in the cytoplasm (schematized in Figure 1B).
The sgRNAs were cloned downstream of the T7 promoter, and the 50
hepatitis delta virus (HDV) ribozyme was introduced between the
sgRNA coding sequence and the T7 RNA polymerase terminator to
induce the formation of mature sgRNAs with unmodified 30 constant
regions.33 The VSV-G-enveloped SpCas9 vesicles were produced in
cell lines stably expressing the T7 RNA polymerase and resistant to
toxicity induced by high levels of uncapped 50-triphosphate cyto-
plasmic RNA generated by this transcriptional system32,34,35 (Fig-
ure S1B). The derived VSV-G-enveloped SpCas9 Vesicles, VEsiCas,
produced in BSR-T7/5 cells expressing sgEGFP5, were verified for
SpCas9 incorporation (Figure S1C), observing that SpCas9 was about
1.5%–2% of the total protein content of VEsiCas (Figure S1D).
VEsiCas produced in BSR-T7/5 cells induced at least 50% loss of
EGFP fluorescence in HEK293-EGFP cells, very similarly to knock-
outs observed with SpCas9-sgRNA plasmid transfection or VEsiCas
treatments of cells pre-transfected with sgEGFP5 (Figure 1C). To
test VEsiCas properties in gene substitution experiments, non-fluo-
rescent cells stably transfected with a single copy of the EGFP Y66S
variant were treated with VEsiCas together with a donor DNA car-
rying a truncated wild-type EGFP sequence corresponding to the
Y66S mutated region. The production of EGFP fluorescent cells indi-
cated proper repair of the EGFP gene by homology-directed repair
(HDR), demonstrating the efficacy of VEsiCas in knockin applica-
tions (Figure S2). VEsiCas were then tested toward two genomic
loci, CXCR4 and VEGFA, commonly used as benchmarks in
genome-editing experiments;11 at these loci, VEsiCas induced similar
percentages of insertions or deletions (indels) as those obtained withSpCas9-sgRNA plasmid transfection (Figures 1D and 1E). These re-
sults were obtained with multiple rounds (three times) of VEsiCas
spinoculation, with single spinoculation treatments producing cumu-
lative editing effects (Figure S3).
SpCas9 pseudotransduction was also tested using lentivirus-based
VLPs (lenti-VLPs). The HIV-1 Gag domain or a reduced portion of
it (MinimalGag) were reported to generate VLPs, described to effi-
ciently transfer protein cargos to recipient cells.36 SpCas9 fused to
Gag or MinimalGag was verified as functionally active in genome ed-
iting activity against the EGFP locus (Figures S4A–S4C). The two
SpCas9-Gag chimeras were used to obtain lenti-VLPs in BSR-T7/5
cells, which produced high percentages of indels in the EGFP,
CXCR4, and VEGFA loci (Figures S4D–S4G). However, because no
dramatic improvements in genome editing efficacy were obtained
with lenti-VLPs, VEsiCas carrying exclusively the VSV-G viral
element were used hereafter.
Overall, our data clearly show that VEsiCas efficiently deliver SpCas9-
sgRNA RNPs free from encoding DNA or additional elements of viral
origin. A key factor to obtain highly efficient genome editing particles
was the relocation of sgRNA expression from the nucleus to the cyto-
plasm of producing cells, which was obtained with cytoplasmic T7
RNA polymerase in appropriate permissive cells.
Multiplexed VEsiCas
Because genome editing applications such as targeted genomic
deletions may require the simultaneous delivery of more than one
sgRNA, we evaluated the possibility to incorporate multiple guides
into VEsiCas (Multi-VEsiCas). Multi-VEsiCas were produced in
BSR-T7/5 cells expressing two T7-driven EGFP-targeting sgRNAs
(sgEGFP5 and sgEGFPBi). Incubation of HEK293-EGFP reporter
cells with Multi-VEsiCas carrying both sgRNAs generated the ex-
pected deletion in the EGFP locus with 17% efficiency, which was
similar to the one obtained with transient transfection of plasmids en-
coding SpCas9 and the corresponding sgRNAs (14%) (Figure 2A).Molecular Therapy: Nucleic Acids Vol. 12 September 2018 455
Figure 3. Genome Editing Activity in Human iPSCs and in the Heart of an EGFP Mouse Model
(A) VEsiCas activity in induced pluripotent stem cells (iPSCs). Shown is the percentage of non-fluorescent iPSCs stably expressing EGFP after treatment with VEsiCas
carrying either sgCtr or sgGFPI2. Data are presented as mean ± SEM for n = 2 independent experiments. (B) VEsiCas-mediated gene disruption in the cardiac muscle of
EGFP mice. Shown are fluorescence microscopy images of cardiac tissue sections from EGFP transgenic mice 10 days after intra-cardiac injection of VEsiCas carrying
sgCtr or sgEGFPBi. DAPI was used as a nuclear counterstain. Immunostaining for a-actinin was performed to identify cardiomyocytes (bottom). A representative sample
of n = 5 experiments is shown. Scale bar, 100 mm. (C) Quantification of VEsiCas EGFP knockout in cardiac tissue. The bar graph shows the percentage of non-fluorescent
cardiomyocytes following VEsiCas treatments (mean ± SEM of n = 5 independent experiments).
Molecular Therapy: Nucleic AcidsConversely, VEsiCas carrying each individual sgRNA (either
sgEGFP5 or sgEGFPBi) were not able to produce any detectable dele-
tion into the target locus (Figure 2A). The flexibility of the VEsiCas
delivery platform was further demonstrated by incorporating the
SpCas9 nickase (SpCas9-n, D10A mutant)37 to generate VEsiCas-n
carrying two closely positioned sgRNAs targeting the EGFP coding
sequence. VEsiCas-n were prepared either with individual sgRNAs
(sgEGFPBi or sgEGFP3gW) or with the sgRNAs in combination
(sgEGFPBi and sgEGFP3gW). A single treatment of HEK293-EGFP
cells with VEsiCas-n carrying both sgRNAs produced a robust
decrease in the number of fluorescent cells (50%), whereas
VEsiCas-n delivering individual sgRNAs did not downregulate
EGFP expression, as expected (Figure 2B). These data indicate that
more than one sgRNA can be delivered simultaneously by VEsiCas,
demonstrating their applicability to generate deletions and to deliver
SpCas9 nickase.
VEsiCas Editing Efficiency in Cells and In Vivo
Increasing amounts of VEsiCas resulted into a proportional increase
in editing activity (Figure S3). Moreover, side-by-side comparison
with electroporation protocols, which are often used to deliver Cas9
into cells for genome editing, revealed that VEsiCas are more efficient.
In fact, compared with electroporation, a lesser amount of SpCas9
delivered by VEsiCas was required to obtain similar percentages of
EGFP knockout cells (Figure S5A). Moreover, viability assays using
the same experimental conditions as in Figure S5A revealed that,
conversely to electroporation, VEsiCas induced minimal cell toxicity
(Figure S5B). The efficacy of VEsiCas was tested in different cell lines,456 Molecular Therapy: Nucleic Acids Vol. 12 September 2018including adherent cells (HeLa), suspension cells (J-Lat-A1), and
human induced pluripotent stem cells (iPSCs) expressing EGFP,
showing a robust decrease in the number of fluorescent cells in all
tested models (Figure 3A; Figure S6). Lastly, VEsiCas were tested in
the cardiac muscle of EGFP transgenic mice. VEsiCas were injected
into the hearts of 5-day-old mice, which were analyzed for levels of
EGFP fluorescence 10 days after treatment. The cardiac tissue from
treated animals was stained using antibodies against a-actinin to spe-
cifically evaluate EGFP fluorescence in cardiomyocytes. As shown in
Figure 3B, large areas of non-fluorescent cardiomyocytes could be
observed close to the VEsiCas injection site. The efficacy of VEsiCas
in vivo editing was quantified by measuring the percentage of EGFP-
negative cardiomyocytes in at least three sections obtained from 5
mice derived from either control (VEsicas sgRNA Ctr) or sgEGFPBi
VEsiCas groups. The data reported in Figure 3C show that, compared
with the control, sgEGFPBi VEsiCas-treated mice showed around
30% more EGFP-negative cardiomyocytes.
Overall, these data show that VEsiCas are efficient tools to deliver
SpCas9 RNPs for genome editing in culture cells as well as in vivo.
Limited Off-Target Activity by SpCas9 Delivered through
VEsiCas
The off-target activity produced by Cas9 is still one of the main
limitations for its therapeutic use. The transient expression of the
nuclease in target cells has been shown to limit non-specific cleav-
ages.13,14 To address this point, the kinetics of SpCas9 intracellular
levels delivered through VEsiCas in comparison with the amounts
Figure 4. Analysis of On/Off-Target Activity
Generated by VEsiCas on the VEGFA Locus
(A) Traceless delivery of SpCas9 through VEsiCas. Shown
is a time course analysis of SpCas9 intracellular levels by
western blot analysis in HEK293T cells transduced
with VEsiCas or transfected with a plasmid expressing
SpCas9. The reported time points correspond to the time
of analysis following treatments (transduction or trans-
fection). The western blot is representative of n = 2 inde-
pendent experiments. (B) Targeted comparison of
genome editing specificity using VEsiCas or a plasmid
expressing SpCas9 in combination with sgVEGFA site3.
Shown are percentages of indel formation measured by
TIDE in the VEGFA site3 locus and in two sgVEGFA site3
previously validated off-target sites (OT1 and OT3) in
HEK293T cells. The dashed bars represent the TIDE
background. (C) Genome-wide specificity of VEsiCas
targeting the VEGFA site3 locus. Shown is GUIDE-seq
analysis for the sgRNA targeting VEGFA site3 locus in
HEK293T cells transfected with SpCas9 or treated with
VEsiCas. The black square indicates on-target sites. DNA
from three biological replicates was mixed before library
preparation. Right: the total number of off-targets identi-
fied for the sgVEGFA site3 with SpCas9 transfection or
VEsiCas treatments.
www.moleculartherapy.orgof nuclease expressed by transfected plasmid were examined.
SpCas9 from VEsiCas was detected in target cells 6 hr after trans-
duction and gradually disappeared within the following 18 hr (Fig-
ure 4A). Conversely, the nuclease intracellular levels produced by an
expression plasmid were clearly detected 12 hr after transfection and
increasingly accumulated thereafter (Figure 4A). To evaluate the
extent of the off-target activity generated by SpCas9 delivered
through VEsiCas or by transfection, indel formation was measured
at two previously validated off-target sites associated with editing of
the VEGFA locus (VEGFA OT1 and OT3).13 Tracking of indels by
decomposition (TIDE) analysis38 revealed that SpCas9 delivered
through VEsiCas produced higher levels of on-target activity than
transfected SpCas9 while causing background levels of indels at
both off-target sites (Figure 4B). Strikingly, compared with the
on-target site, VEsiCas produced at least 22- and 17-fold less indels
at OT1 and OT3, respectively, whereas transfected SpCas9 cleaved
OT1 similarly to the on-target site, and OT3 was edited just 5 times
less. A deeper off-target analysis of the VEGFA locus was performed
through genome-wide unbiased identification of double strand
breaks (DSBs) enabled by sequencing (GUIDE-seq),39 a genome-
wide approach (Figure 4C). This analysis revealed that SpCas9Molecular Therapexpressed from a transfected plasmid cleaved
a total number of 87 off-target sites, five of
them with a higher number of GUIDE-seq
reads (1,026, 635, 509, 417, and 291, respec-
tively) than the on-target site (253 reads).
Conversely, GUIDE-seq analysis in VEsiCas-
treated cells detected exclusively a single off-
target site, with hundreds less GUIDE-seq
reads than on-target (355 reads on-target and11 reads off-target) and a 37 times improved on/off-target ratio
compared with plasmid transfection.
In conclusion, the off-target analysis performed on the VEGFA locus,
a gold standard for the evaluation of SpCas9 specificity,11 revealed
that VEsiCas produced a more specific genomic modification, which
correlates with the rapid clearance of the nuclease from the target
cells.
DISCUSSION
The CRISPR-Cas9 technology is a powerful tool for genome editing.
Its translation into clinical use strongly depends on further improve-
ments in specificity (complete abrogation of off-target activity) and
delivery. These are tightly interdependent aspects of genome editing
because the amount and time of Cas9 expression in recipient cells
strongly correlate with the frequencies of off-target cleavages.13,14,40
Moreover, persistence of Cas9 expression may generate adverse im-
mune responses toward the modified cells in vivo, further reinforcing
the demand for a highly controllable method of delivery.41 Transient
expression of Cas9 has been obtained through physical and chemical
delivery methods,14,16, which are not ideal for in vivo applications.18y: Nucleic Acids Vol. 12 September 2018 457
Molecular Therapy: Nucleic AcidsPremiere tools for in vivo gene delivery are viral vectors, which, how-
ever, have serious limitations deriving from their potential risk of
insertional mutagenesis13,21 and permanent transgene expression
that may increase the number of SpCas9 off-target cleavages.42
Genotoxicity associated with viral integration can be partially circum-
vented by using non-integrating viral vectors such as those derived
from AAVs).24,43 Because of size limitations, SpCas9 orthologs,
such as the one from Staphylococcus aureus,44 or split-protein strate-
gies (split-Cas9) have generally been employed with AAV vectors.45
However, the separation of CRISPR elements introduces high
complexity into the system, and occasional AAV integrations have
been reported.43 Similarly, unpredictable insertional mutagenesis
reported with other non-integrating vectors, such as IDLVs, can be
enhanced by nuclease activity beyond the background level.46,47
Attempts to combine the advantages offered by viral delivery together
with transient SpCas9 expression were recently addressed by using a
self-limiting CRISPR-Cas9 lentiviral vector13 and by engineering len-
tiviral particles containing pre-packaged SpCas9 together with a non-
integrating lentiviral vector expressing the sgRNAs.25 A further step
toward the exploitation of viral delivery properties in a DNA-free
context is the development of VLPs,26,28 which have mainly been
used in the past decade for vaccination approaches27 and for the de-
livery of exogenous proteins.26,28 In this study, we explored the use of
lentivirus-based VLPs for the delivery of SpCas9 fused to HIV-1 Gag
in the absence of a viral transfer genome. To further abandon viral
elements for the production of vesicles, we exploited the fusogenic
properties of VSV-G alone, which is sufficient for the delivery of
protein cargos.29 We discovered that VSV-G vesicles, in combination
with SpCas9, were sufficiently loaded with SpCas9 protein. However,
vesicles produced under standard experimental conditions using
nuclear U6-based transcription for sgRNA synthesis showed poor
genome-editing activity, suggesting non-sufficient amounts of
incorporated sgRNA. This limitation was circumvented by
favoring SpCas9 protein assembly with the sgRNA in producing cells
through cytoplasmic sgRNA synthesis driven by the T7 RNA
polymerase. To this end, we employed cells resistant to cytotoxicity
induced by high levels of uncapped 50-triphosphate cytoplasmic
RNA, BSR-T7/5.32
A remarkable advantage offered by the VEsiCas approach is the tran-
sient nature of delivered SpCas9. As demonstrated in this study, the
rapid clearance of SpCas9, which decreased as soon as 12 hr after
VEsiCas treatment, strongly lowered the off-target activity associated
with genome editing, as opposed to high levels of non-specific cleav-
ages generated by plasmid transfection. Our data also prove that
VEsiCas are more efficient and less toxic in delivering SpCas9
RNPs than electroporation. In fact, our system requires less SpCas9
protein, offering a clear advantage in preventing potential adverse
effects of immune responses against the edited cells.41
Eventually, VEsiCas can be readily adapted to more complex
genome-editing approaches, such as the use of Cas9 nickase,
requiring incorporation of sgRNAs pairs; their use with other
emerging RNA-guided nucleases can also be envisioned.48458 Molecular Therapy: Nucleic Acids Vol. 12 September 2018Overall, the efficient and traceless delivery of CRISPR-Cas9 through
the VEsiCas approach represents a further advancement toward safer
in vivo genome editing.
MATERIALS AND METHODS
Plasmids and Oligonucleotides
The sgRNAs for the initial experiments on VSV-G vesicle production
were transcribed from a U6 promoter-driven cassette derived from
pX330 (a gift from Feng Zhang, Addgene 42230)1 and cloned into
the pUC19 plasmid.13 sgRNA oligos were cloned using a double
BbsI site inserted before the sgRNA constant portion according to a
previously published cloning strategy.1 The Gag-SpCas9 plasmid
was obtained through the fusion of the Gag coding sequence with
3FLAG-SpCas9 encoded by the pX-SpCas9 vector.13 pX-SpCas9
was obtained by removal of an NdeI fragment including the sgRNA
expression cassette from pX330 and was used to express SpCas9.
MinimalGag-Cas9 was assembled in pCDNA3 by subcloning the
SpCas9 coding sequence from pX-SpCas9 and MinimalGag from
the D-Zwt-p2b plasmid,36 a generous gift from H.G. Gottlinger.
Afterward, an additional version of both constructs was obtained
by removing, through site-directed mutagenesis, a methionine in
the linker peptide derived from pX-Cas9 that led to unfused SpCas9
production (Figure S4).
For VLP and VEsiCas production in BSR-T7/5 cells, sgRNAs were
transcribed from a pVAX-T7-sgRNA expression plasmid having a
T7 promoter-driven cassette cloned into the pVAX plasmid at the
NdeI site. sgRNA oligos were cloned in pVAX-T7-sgRNA using a
double BsmBI site inserted before the sgRNA constant portion
(a list of oligonucleotides used to clone sgRNAs is available in
Table S1). pVAX-T7-sgRNA included a 50 HDV ribozyme33 designed
to cleave the 30 end of the sgRNA containing the T7 terminator and
the ribozyme itself. The Cas9-nickase construct was obtained by in-
serting the D10A mutation in the SpCas9 coding sequence. The T7
RNA polymerase coding sequence was amplified from the genome
of BSR-T7/5 cells and cloned in place of EGFP into the pEGFP-N1
plasmid using the HindIII/XbaI sites to obtain the pKANA-T7-
RNA-Pol plasmid. Plasmids were verified by Sanger sequencing.
Information regarding relevant plasmid DNA sequences produced
for this manuscript can be found in the Supplemental Information.
Cell Cultures and Transfection
BHK21-derived producing cells stably expressing T7 polymerase
(BSR-T7/5) were a kind gift from Karl Conzelmann (Ludwig-
Maximilians-Universität, Munich, Germany).31 To select cells that
retain the T7 RNA polymerase construct, the medium was supple-
mented with 1 mg/mL G418 (Gibco-Life Technologies). HEK293T
cells were obtained from the ATCC. HEK293-EGFP cells were
generated by stable transfection of pEGFP-IRES-Puro and selected
with 1 mg/mL of puromycin.13 BHK-21 (ATCC CCL-10), Vero
(ATCC-CCL-81), HeLa (ATCC-CCL-2), and all cell lines described
above were cultured in DMEM supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS), 2 mM L-glutamine, 10 U/mL
penicillin, and 10 mg/mL streptomycin. J-Lat-A1 are Jurkat cells
www.moleculartherapy.orgthat have been latently transduced by an HIV-1 vector encoding
EGFP.49 J-Lat-A1 cells were cultured in RPMI medium supple-
mented with 10% FBS and penicillin and streptomycin (pen/strep)
antibiotics. EGFP expression was induced with 10 nM TPA
(12-O-tetradecanoylphorbol-13-acetate) treatment for 24 hr. To
obtain HeLa-EGFP, HeLa cells were transfected with the pEGFP-C1
plasmid (Clontech Laboratories) using FuGENE HD transfection re-
agent (Promega). After selection in culture medium with 400 mg/mL
G418 (Life Technologies) for approximately 10 days, cells expressing
high levels of EGFP were enriched by fluorescence-activated cell
sorting (FACS) and propagated as a polyclonal cell population. Stock
cultures of HeLa-EGFP cells (95% EGFP-positive cells) were main-
tained in culture medium supplemented with 200 mg/mL G418.
Transgenic human iPSCs constitutively expressing GFP were derived
from a commercial human episomal iPSC line (Gibco, Thermo
Fisher Scientific) originally derived from CD34+ cord blood using
an EBNA-based episomal system. Human iPSC clones stably ex-
pressing copGFP under control of the ubiquitous cytomegalovirus
promoter were generated by infection with the pGZ-CMV-copGFP
lentiviral vector (System Biosciences). Zeocin-based clone selection
was started 72 hr after infection for 7 days. Resistant colonies were
manually picked, expanded clonally, and characterized for their
pluripotency competence. Human iPSC lines were grown on
feeder-free Geltrex-coated dishes and cultured in StemMACS iPS-
Brew XF medium (Miltenyi Biotec). All cell lines were verified to
be mycoplasma-free (PlasmoTest, InvivoGen).
Transfection experiments were performed in 12–24 multi-well plates
with 250–1,000 ng of each plasmid using the TransIT-LT1 (Mirus) re-
agent according to manufacturer’s instructions. Cells were collected
2–4 days after transfection or as described.
Gene substitution experiments through HDR of the EGFP-Y66S gene
were performed using previously described cells and donor DNA.13
Briefly 293-iY66S cells (Flp-In T-REx system, Life Technologies)
were generated by Flp-mediated recombination of the pcDNA5-
FRT-TO-EGFP-Y66S plasmid in cells carrying a single genomic FLP
recombinase target (FRT) site and stably expressing the tetracycline
repressor. 293-iY66S cells were cultured in selective medium contain-
ing 15 mg/mL blasticidin and 100 mg/mL hygromycin (Life Technolo-
gies). 293-iY66S cells were transfected in 24 multi-wells with 1 mg of
pcDNA5-FRT-TO-rEGFP(1-T203K-stop) donor plasmid together
with either 500 ng of pcDNA3.1 or 250 ng of pX-Cas9 and 250 ng
of pUC19 plasmid encoding sgRNAEGFPBi or control sgRNA (sgCtr)
using TransIT-LT1 (Mirus Bio) according to manufacturer’s instruc-
tions. 16 hr after transfection with the donor plasmid, cells were
washed with newmedium and treated with VEsiCas (1 mg Cas9). Cells
were collected and analyzed 4 days after treatment. The expression
of EGFP was induced by treatment with 100 ng/mL doxycycline
(Cayman Chemical) for 20 hr before fluorescence measurement.
VSV-G/SpCas9 Vesicles, Lenti-VLPs, and VEsiCas Production
For VSV-G/Cas9 vesicle production, a 100-mm dish of confluent
HEK293T cells was transfected with 15 mg of pxCas9, Gag-SpCas9,or pCDNA3-MinGag-Cas; 15 mg of the desired pUC-U6-sgRNA;
and 3 mg of VSV-G plasmids using the polyethyleneimine (PEI)
method.50 Subsequent productions were performed in BSR-T7/5 cells
using the conditions reported above, except for the pVAX-T7-sgRNA
plasmid, which substituted pUC-U6-sgRNA for RNA guide expres-
sion. For Multi-VEsiCas deletion experiments, 7.5 mg of each
pVAX-T7-sgRNA (sgEGFP5 and sgEGFPBi) targeting EGFP was
used for particle production. For VEsiCas-n production, 15 mg of
Cas9-Nickase plasmid and 7.5 mg of each pVAX-T7-sgEGFPBi and
pVAX-T7-sgEGFP3gW were used. After 12 hr of incubation, the me-
dium was replaced with fresh complete DMEM, and 48 hr later, the
supernatant was collected, centrifuged at 400  g for 5 min, and
filtered through a 0.22 mm polyethersulfone (PES) filter. VLPs and
VEsiCas were then concentrated and purified through a 20% sucrose
cushion by ultracentrifugation for 2 hr at 150,000  g (4C) and sus-
pended in suitable volumes of complete medium (DMEM, RPMI,
or StemMACS iPS-Brew XF medium, according to the target cells)
or 1 PBS for mouse injections and stored at 80C. The amount
of SpCas9 or Gag-SpCas9 and MinGag-SpCas9 chimeras produced
in the VSV-G vesicles was evaluated through western blot analysis us-
ing purified SpCas9 as a standard. Unless indicated, for each single
transduction experiment we used vesicles containing about 1 mg of
SpCas9. The reference recombinant SpCas9 protein was produced
in bacteria (see below) according to Gagnon et al.51 and quantified
through Coomassie staining. The efficiency of SpCas9 incorporation
into VEsiCas was obtained through a western blot ratio of incorpo-
rated SpCas9 protein on the total amount of proteins quantified in
VEsiCas by Bradford assay (Bio-Rad).
Delivery in Target Cells
The day before transduction, 1  105 HEK293T, HEK293-EGFP,
HeLa-EGFP, or J-LAT-A1 cells were seeded in a 24-well plate.
VEsiCas and VLPs were delivered into target cells by spinoculation
for 2 hr at 1,600 g at 20C (30min at 1,000 g and 24C for human
iPSCs), followed by overnight incubation at 37C. J-Lat-A1 cells were
induced by TPA (Sigma-Aldrich) and analyzed for genome editing
3 days after the last transduction or, for EGFP reduction, at least
7 days after the treatment. For VEGFA and CXCR4 loci, triple trans-
duction experiments were performed. Cells were trypsinized 24 hr af-
ter each transduction; 2/3 of cells were collected for genomic analysis
and 1/3 was subcultured for following treatments, one every 48 hr.
Cells were collected for final analysis 3 days after the last treatment.
SpCas9-sgRNA Electroporation
Recombinant SpCas9 protein was produced in bacteria according to
Gagnon et al.51 Briefly, the pET-28b-Cas9-His plasmid (a gift from
Alex Schier, 47327) was used to express SpCas9 in E. coli Rosetta cells
(Novagen), which were grown for 12 hr at 37C, followed by 24 hr
induction at 18C. Purification was performed on his-tag resin
(G-Biosciences), and the column was washed with 20 mM Tris
(pH 8), 30 mM imidazole, and 500 mM NaCl and eluted with
20 mM Tris (pH 8), 500 mM imidazole, and 500 mM NaCl. After
dialysis into 20 mM Tris, 200 mM KCl, and 10 mM MgCl2, single-
use aliquots were stored at 80C. To produce in vitro-transcribedMolecular Therapy: Nucleic Acids Vol. 12 September 2018 459
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sgCtr with primers T7 promoter forward (fw) and gRNA end reverse
(rev) (Table S2). This PCR product, containing the T7 promoter and
the complete sequence of the sgRNA, was used for in vitro transcrip-
tion using the HiScribe T7 High Yield RNA Synthesis Kit (New
England Biolabs) following the manufacturer’s instructions. TRIzol
(Invitrogen)-purified sgRNAs, precipitated with isopropanol and
washed with 75% ethanol, were analyzed by acrylamide gel electro-
phoresis and quantified using a NanoDrop spectrophotometer
(Thermo Fisher Scientific). Purified sgRNAs were mixed with recom-
binant SpCas9 immediately before electroporation by incubating
12.4 mg of SpCas9 with 3.1 mg of sgRNA (or as indicated with a 4:1
mass ratio between protein and RNA) in 20 mM 4-(2-hydrox-
yethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.5), 150 mM
KCl, 1 mM MgCl2, 10% (v/v) glycerol, and 1 mM DTT at 37C for
10 min. 2.5  105 HEK293-EGFP cells were nucleofected using the
Q001 protocol in 120 mM K2HPO4/KH2PO4 (pH 7.2), 15 mM
MgCl2, 10 mM glucose, and 5 mM KCl using Lonza Nucleofector
II. Cells were analyzed for EGFP loss 7 days after electroporation.
Viability Assay
48 hr following VEsiCas spinoculation or RNP electroporation,
HEK293-EGFP cells were collected, and the viability was measured
with the Vybrant MTT Cell Proliferation Assay Kit (Thermo Fisher
Scientific) according to the manufacturer’s instructions.
Detection of SpCas9-Induced Mutations
EGFP expression was analyzed with the Invitrogen Tali image-
based cytometer. In the comparative analysis with electroporated
RNPs, analysis of EGFP expressing cells was performed by FACS
(FACSCanto, BD Biosciences). To detect indels in the CXCR4 and
VEGFA loci, genomic DNA was isolated using the DNeasy Blood &
Tissue Kit (QIAGEN). PCRs on purified genomic DNA were per-
formed using Phusion High-Fidelity DNA polymerase (Thermo
Fisher Scientific). Samples were amplified using the oligonucleotides
listed in Table S2. Purified PCR products were analyzed by
sequencing and applying the TIDE tool.38 Detection of the deletion
in the EGFP locus after Multi-VEsiCas treatment was revealed by
PCR amplification using oligonucleotides EGFP fw and EGFP rev.
GUIDE-Seq
2  105 HEK293T cells were transfected with 750 ng of SpCas9-
expressing plasmid together with 250 ng of VEGFA site3 sgRNA-
coding plasmid or an empty pUC19 plasmid, 10 pmol of the bait
double-stranded oligodeoxynucleotide (dsODN) containing phos-
phorothioate bonds at both ends (designed according to the original
GUIDE-seq protocol39), and 50 ng of a pEGFP-IRES-Puro plasmid
expressing both EGFP and the puromycin resistance gene. VEsiCas
targeting VEGFA site3 were delivered by spinoculation 6 hr following
transfection of dsODN and pEGFP-IRES-Puro coding plasmids. The
following day, cells were trypsinized and replated. The procedure was
repeated every 48 hr. After the last treatment, cells were detached and
selected with 2 mg/mL of puromycin for 48 hr. Cells were then
collected, and genomic DNA was extracted using the DNeasy Blood460 Molecular Therapy: Nucleic Acids Vol. 12 September 2018and Tissue Kit (QIAGEN) following the manufacturer’s instructions
and sheared to an average length of 500 bp with the Bioruptor Pico
sonication device (Diagenode). Library preparations were performed
with the original adapters and primers according to previous work.39
Libraries were quantified with the Qubit dsDNA High Sensitivity
Assay Kit (Invitrogen) and sequenced with theMiSeq sequencing sys-
tem (Illumina) using an Illumina Miseq Reagent kit V2, 300 cycles
(2  150 bp paired end). Raw sequencing data (FASTQ files) were
analyzed using the GUIDE-seq computational pipeline.39 After de-
multiplexing, putative PCR duplicates were consolidated into single
reads. Consolidated reads were mapped to the human reference
genome GrCh37 using BWA-MEM37; reads with a mapping quality
lower than 50 were filtered out. Upon identification of the genomic
regions integrating dsODNs in aligned data, off-target sites were re-
tained when at most eight mismatches against the target were present
and absent in the background controls. Visualization of aligned off-
target sites is available as a color-coded sequence grid. Off-target sites
detected are listed in Table S3.
Western Blots
Collected cells or supernatants containing VSV-G vesicles were lysed
in NEHN buffer (20mMHEPES [pH 7.5], 300mMNaCl, 0.5%NP40,
1 mM EDTA, and 20% glycerol) supplemented with 1% of protease
inhibitor cocktail (Pierce). Protein extracts were separated by SDS-
PAGE using the PageRuler Plus Protein Standards as the standard
molecular mass markers (Thermo Fisher Scientific). After electropho-
resis, samples were transferred onto 0.22 mm PVDF membranes
(GE Healthcare). The membranes were incubated with mouse anti-
FLAG (Sigma) for detecting Gag-Cas9, MinGag-Cas9, and SpCas9
and mouse anti-a-tubulin (Sigma) and with the appropriate horse-
radish peroxidase (HRP)-conjugated goat anti-mouse (Kirkegaard
& Perry Laboratories [KPL]) secondary antibody for enhanced
chemiluminescence (ECL) detection. The Guide-it Cas9 monoclonal
antibody (clone TG8C1) (Clontech) was used to quantify SpCas9 by
western blotting using recombinant SpCas9 as a reference. Images
were acquired and bands were quantified using the UVItec Alliance
detection system.
In Vivo Delivery of VEsiCas
Animal care and treatments were conducted in conformity with insti-
tutional guidelines in compliance with national and international
laws and policies (European Economic Community [EEC] Council
Directive 86/609, OJL 358, December 12, 1987 and D.lgs 116/92)
upon approval by the International Centre for Genetic Engineering
and Biotechnology (ICGEB) Ethical Committee for Animal Experi-
mentation and by the Italian Ministry of Health. Transgenic mice
(males) expressing EGFP (C57BL/6-Tg(CAG-EGFP)1Osb/J from
The Jackson Laboratory) on post-natal day 5 were anesthetized by
hypothermia on ice for 3–5 min, placing a gauze below the pup
to avoid direct contact with ice. A transverse skin incision across
the lower half of the chest was performed using small scissors,
followed by gentle separation of the skin from underlying muscle
by using blunt dissection. A lateral tracheotomy was created by
making a small incision at the fourth intercostal space to visualize
www.moleculartherapy.orgthe heart. VEsiCas (5 mL, corresponding to 4 mg of SpCas9) carrying
sgCtr or a guide targeting EGFP (sgEGFPBi) were injected into the left
ventricular anterior wall using a 31G needle (n = 5 per group). The
ribs and the skin were sutured together using an 8-0 nonabsorbable
prolene suture to seal the chest wall incision. The neonates were
warmed rapidly under a heat lamp for several minutes until recovery
and re-introduced to the mother. After 10 days, the hearts were
collected, fixed in 4% paraformaldehyde, and snap-frozen in isopen-
tane and liquid nitrogen for fluorescence microscopy analysis.
Immunofluorescence and Image Analysis
Frozen sections were washed 3 times in PBS, permeabilized in 0.5%
Triton X-100 for 30 min, and blocked in 10% goat serum for 1 hr.
Sections were stained overnight at 4Cwith anti-sarcomeric a-actinin
antibodies (Abcam) 1:100 in 5% goat serum. After 2 washing steps of
5 min in 0.5% Triton X-100 at room temperature, sections were incu-
bated 1 hr in 1:200 anti-mouse secondary antibody conjugated to
Alexa Fluor 594 (Life Technologies) in 10% goat serum for 45 min
at room temperature. Nuclei were stained with DAPI solution
(Sigma). Quantification of EGFP-positive cardiomyocytes was per-
formed on 10 images of coronal heart sections, corresponding to
a 2 mm2 area of the left ventricular anterior wall, surrounding the
injection site. At least 3 different sections and 10 images per animal
were used for the quantification (50 images per group). Data are
expressed as the percentage of EGFP-positive cardiomyocytes over
the total number of a-actinin-labeled cardiomyocytes.
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